ATE420657T1 - Archaeosome als adjuvantien und träger für azelluläre impstoffe zur induktion einer zytotoxischen t-lymphozyten (ctl) immunantwort - Google Patents

Archaeosome als adjuvantien und träger für azelluläre impstoffe zur induktion einer zytotoxischen t-lymphozyten (ctl) immunantwort

Info

Publication number
ATE420657T1
ATE420657T1 AT00967482T AT00967482T ATE420657T1 AT E420657 T1 ATE420657 T1 AT E420657T1 AT 00967482 T AT00967482 T AT 00967482T AT 00967482 T AT00967482 T AT 00967482T AT E420657 T1 ATE420657 T1 AT E420657T1
Authority
AT
Austria
Prior art keywords
antigen
ctl
vaccines
lymphocyte
response
Prior art date
Application number
AT00967482T
Other languages
English (en)
Inventor
G Sprott
Lakshmi Krishnan
J Conlan
Girishchandra Patel
Gordon E Willick
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of ATE420657T1 publication Critical patent/ATE420657T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00967482T 1999-10-12 2000-10-12 Archaeosome als adjuvantien und träger für azelluläre impstoffe zur induktion einer zytotoxischen t-lymphozyten (ctl) immunantwort ATE420657T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15894499P 1999-10-12 1999-10-12
US20998800P 2000-06-08 2000-06-08

Publications (1)

Publication Number Publication Date
ATE420657T1 true ATE420657T1 (de) 2009-01-15

Family

ID=26855522

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00967482T ATE420657T1 (de) 1999-10-12 2000-10-12 Archaeosome als adjuvantien und träger für azelluläre impstoffe zur induktion einer zytotoxischen t-lymphozyten (ctl) immunantwort

Country Status (8)

Country Link
EP (1) EP1223978B9 (de)
JP (1) JP2003511421A (de)
AT (1) ATE420657T1 (de)
AU (1) AU7767000A (de)
CA (1) CA2389652A1 (de)
DE (1) DE60041413D1 (de)
ES (1) ES2320971T3 (de)
WO (1) WO2001026683A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2347421T3 (es) * 2001-08-03 2010-10-29 National Research Council Of Canada Liposomas preparados a partir de lipidos extraibles de mycobacterium.
GB0212666D0 (en) 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
CA2647060C (en) * 2006-03-30 2014-10-21 National Research Council Of Canada Synthetic archaeal glycolipid adjuvants
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US20080220028A1 (en) * 2006-12-15 2008-09-11 National Research Council Of Canada Archaeal polar lipid aggregates for administration to animals
US8916164B2 (en) * 2007-08-29 2014-12-23 Abivax Methods of enhancing adjuvaticity of vaccine compositions
KR20100000146A (ko) * 2008-06-24 2010-01-06 주성엔지니어링(주) 챔버리드를 포함하는 기판처리를 위한 진공챔버
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
JP2013166699A (ja) * 2010-05-28 2013-08-29 National Institute Of Infectious Diseases 不活化したウイルス粒子を含む複合体及びその用途
WO2016004512A1 (en) * 2014-07-11 2016-01-14 National Research Council Of Canada Sulfated-glycolipids as adjuvants for vaccines
FR3052361B1 (fr) 2016-06-09 2019-08-23 Centre National De La Recherche Scientifique Diethers d’archaea lipides synthetiques
AU2017341735B2 (en) 2016-10-11 2022-01-13 Helmholtz Center for Infection Research Hepatitis C virus immunogenic compositions comprising as an adjuvant a cyclic dinucleotide or an archaeosome and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502087A (ja) * 1995-12-15 2000-02-22 ナショナル リサーチ カウンシル オブ カナダ アジュバンドおよび送達賦形剤としての、アーケオソーム類、補酵素ｑ▲下１０▼を含有するアーケオソーム類、および補酵素ｑ▲下１０▼を含有する他の種類のリポソーム類
DE69828414T2 (de) * 1997-09-11 2005-12-01 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mukosale zytotoxische t-lymphozytenantwort

Also Published As

Publication number Publication date
AU7767000A (en) 2001-04-23
JP2003511421A (ja) 2003-03-25
EP1223978B9 (de) 2009-09-16
ES2320971T3 (es) 2009-06-01
EP1223978B1 (de) 2009-01-14
EP1223978A2 (de) 2002-07-24
WO2001026683A2 (en) 2001-04-19
CA2389652A1 (en) 2001-04-19
DE60041413D1 (de) 2009-03-05
WO2001026683A3 (en) 2001-10-18

Similar Documents

Publication Publication Date Title
DE60041413D1 (de) Archaeosome als adjuvantien und träger für azelluläre impstoffe zur induktion einer zytotoxischen t-lymphozyten (ctl) immunantwort
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
MXPA01007760A (es) Compuesto adyuvante inmunologico.
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
AR014182A1 (es) Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
PL2068918T3 (pl) Kompozycja szczepionki zawierająca syntetyczny adiuwant
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
NO930938D0 (no) Forbedrede vaksiner
PT625053E (pt) Vacina a base de urease contra a infeccao por helicobacter
ATE489968T1 (de) Proteosom-liposaccharid-vakzine-adjuvans
CA2476571A1 (en) Method for isolating ligands
Rolph et al. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
ES2019728A6 (es) Procedimiento de preparacion de una vacuna de inmunoterapia para tumores de melanoma.
NO924271D0 (no) Vaksiner med forbedret immunogenisitet
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
EA200800917A1 (ru) Адъюванты для вакцин
ATE329615T1 (de) Borrelia burgdorferi bacterin
ATE374622T1 (de) Genetische impstoffe mit adjuvans
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
Margos et al. Gerbu adjuvant modulates the immune response and thus the course of infection in C56BL/6 mice immunised with Echinococcus multilocularis rec14-3-3 protein
SE9600646D0 (sv) Vaccin
Lövgren B. Morein, M. Villacres-Eriksson, L. Åkerblom and
Lebowitz et al. A nanoparticle therapeutic vaccine targeting HAAH stimulates cellular immunity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties